As of Jan 13
| +0.17 / +2.17%|
The 5 analysts offering 12-month price forecasts for Aratana Therapeutics Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 10.00. The median estimate represents a +37.16% increase from the last price of 8.02.
The current consensus among 6 polled investment analysts is to Buy stock in Aratana Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.